-

$undefined

N/A

(N/A)

Dogwood Therapeutics NasdaqCM:DWTX Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.

Location: 44 Milton Avenue, Alpharetta, GA, 30009, United States | Website: https://dwtx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

93.42M

Cash

17.54M

Avg Qtr Burn

-3.134M

Short % of Float

11.77%

Insider Ownership

13.07%

Institutional Own.

7.95%

Qtr Updated

03/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IMC-1 (famciclovir + celecoxib) Details Fibromyalgia	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Halneuron Details Chemotherapy-induced neuropathic pain	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-2 (valacyclovir and celecoxib) Details Long COVID-19	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.